

## AMGEN INTRODUCES THE NPLATE FIRST STEP™ PROGRAM

Helps your commercially insured patients appropriate for Nplate® treatment meet their out-of-pocket costs

Amgen is committed to helping your patients access our medicines.

The Nplate FIRST STEP™ Program is a coupon co-pay program that helps eligible patients meet their Nplate® deductible, co-insurance, and/or co-payment (out-of-pocket) requirements.

Patients and providers must be enrolled in the Nplate® NEXUS (Network of Experts Understanding and Supporting Nplate® and Patients) Program. The Nplate FIRST STEP™ Program is not valid in Massachusetts or where otherwise prohibited by law. Patients may not participate in Medicare, Medicaid or other federally funded healthcare programs. Certain other restrictions and eligibility requirements apply. Log on to [www.AmgenFIRSTSTEP.com](http://www.AmgenFIRSTSTEP.com) or call 1-888-657-8371 for complete list of eligibility requirements and program restrictions.



- No income eligibility requirement
- No out-of-pocket for initial injection
- Maximum out-of-pocket costs for subsequent injections is \$25\*
- One simple phone call to enroll

\*Total program benefits may not exceed \$5,000 per patient per six-month period as defined by the program.

**Enroll your clinic or institution today. Call 1-888-65-STEP1 (1-888-657-8371) between 9 AM and 8 PM EST or visit [www.AmgenFIRSTSTEP.com](http://www.AmgenFIRSTSTEP.com) for more information**

## INDICATION

Nplate® (romiplostim) is indicated for the treatment of thrombocytopenia in patients with chronic immune (idiopathic) thrombocytopenic purpura (ITP) who have had an insufficient response to corticosteroids, immunoglobulins, or splenectomy. Nplate® should be used only in patients with ITP whose degree of thrombocytopenia and clinical condition increases the risk for bleeding. Nplate® should not be used in an attempt to normalize platelet counts.

## IMPORTANT SAFETY INFORMATION

Serious adverse reactions associated with Nplate® in clinical studies were bone marrow reticulin deposition and worsening thrombocytopenia after Nplate® discontinuation. Additional risks include Bone Marrow Fibrosis, Thrombotic/Thromboembolic Complications, Lack or Loss of Response to Nplate®, Hematological Malignancies and Progression of Malignancy in Patients with a Pre-existing Hematological Malignancy or Myelodysplastic Syndrome (MDS). Nplate® is not indicated for the treatment of thrombocytopenia due to MDS or any cause of thrombocytopenia other than chronic ITP. Monitor CBCs, including platelet counts and peripheral blood smears, prior to initiation, throughout, and following discontinuation of Nplate® therapy. Nplate® is available only through a restricted distribution program called Nplate® NEXUS (Network of Experts Understanding and Supporting Nplate® and Patients) Program. In the placebo-controlled studies, headache was the most commonly reported adverse drug reaction.

If you have any questions about this information, be sure to discuss them with your doctor. You are encouraged to report negative side effects of prescription drugs to the FDA.

Visit [www.fda.gov/medwatch](http://www.fda.gov/medwatch) or call 1-800-FDA-1088.

Please see the accompanying full Prescribing Information and Medication Guide for Nplate®.

Bankcorp is the issuer of the Nplate FIRST STEP™ Program MasterCard®.



© 2010 Amgen. All rights reserved.  
MC52027-D 10M/11-10 P44192  
[www.Nplate.com](http://www.Nplate.com)

